✓ Last verified: March 27, 2026 — Edited & verified by Angelica Bottaro for HealingMaps Editorial Staff
Known For: Led by neuropsychiatrist and Chief Medical Officer Dr. Teresa Poprawski, offering Spravato and TMS alongside full psychiatric services — making it one of the Milwaukee metro’s most insurance-friendly interventional psychiatry practices.
| Review Scores | Established interventional psychiatry practice with neuropsychiatrist leadership |
| Location | West Allis, WI |
| Address | 2448 S 102nd Street, Suite 180, West Allis, WI 53227 |
| Phone | (844) 731-7543 |
| Website | reliefmh.com |
| Treatments | Spravato (Esketamine) Nasal Spray, Transcranial Magnetic Stimulation (TMS), Psychiatric Services, Therapy |
| Conditions Treated | Treatment-Resistant Depression, Anxiety, OCD |
| Cost | Contact for pricing; most major insurance plans accepted |
| Insurance | Works with most insurance plans |
| Clinical Lead | Dr. Teresa Poprawski, MD (Neuropsychiatrist & Chief Medical Officer); Maggie Schauer, PA-C; Michael Henderson, APNP, PMHNP |
HealingMaps Take: Relief Mental Health’s West Allis clinic brings something rare to the Milwaukee interventional psychiatry market: a practice led by a credentialed neuropsychiatrist (Dr. Teresa Poprawski) who also serves as Chief Medical Officer of the organization. That combination — active clinical practice plus organizational leadership — typically yields careful protocols and evidence-based treatment selection. Offering Spravato AND TMS under one roof means patients who don’t respond to one modality can pivot without switching clinics, which matters because neither treatment works for every patient. The Mental Health team’s multi-clinician structure — psychiatrist, physician assistant, psychiatric nurse practitioner, and licensed clinical social worker — creates a genuine treatment home where Spravato can be coordinated with therapy and medication management. Insurance acceptance across most major Wisconsin plans is a meaningful competitive advantage; many Milwaukee interventional psychiatry options are cash-only. The West Allis location is 15-20 minutes from downtown Milwaukee and serves the western suburbs (Elm Grove, Greenfield, Wauwatosa), filling a geographic gap for patients outside downtown Milwaukee who would otherwise drive to Brookfield or further.
Market Position: Relief Mental Health is a Spravato-certified clinic in the Milwaukee metro. Spravato (esketamine) is the FDA-approved ketamine treatment that most commercial insurance plans cover after prior authorization — unlike cash-pay IV ketamine.
Industry pricing reference. Relief Mental Health has not published specific per-session pricing — contact the clinic directly for a quote. The calculator above shows typical metro-level cost estimates across protocols, not this clinic’s specific prices.
| Protocol | Typical Industry Cost | Offered Here |
|---|---|---|
| IV Ketamine | $350–$650/session | — |
| Spravato (esketamine) | $0–$250 copay (insured) | ✓ Yes |
| IM Ketamine | $250–$400/injection | — |
| KAP (with therapist) | $400–$1,200/session | — |
| At-home troches | $150–$300/month | — |
This 3-question summary is matched to the protocols and conditions Relief Mental Health treats. Editorial responses are HealingMaps-authored, grounded in our 2026 Ketamine Clinic Intelligence Report.
Yes — Relief Mental Health offers Spravato, which means they’re FDA REMS-certified and maintain the required two-hour in-office monitoring window after each dose. Spravato is the primary insurance-covered ketamine option for treatment-resistant depression. Worth confirming the prior-authorization timeline before booking your first session.
Relief Mental Health treats depression via Spravato (FDA-approved for TRD). The Spravato pathway is the most likely to obtain commercial insurance coverage. TRD is typically defined as two or more prior antidepressant trials without sufficient response — patients meeting that bar are best candidates here.
Yes — Relief Mental Health treats anxiety, including generalized anxiety, social anxiety, and panic disorder. The evidence base for ketamine in anxiety is less robust than for depression, but it can be a meaningful option for patients who haven’t responded to SSRIs or benzodiazepines. Worth asking which of their protocols they typically recommend for anxiety-primary patients.
Leave a Reply